Improved small airway dysfunction in severe asthma with clinical remission by anti-interleukin-5/interleukin-5 receptor α

Ann Allergy Asthma Immunol. 2024 May;132(5):648-650. doi: 10.1016/j.anai.2024.02.006. Epub 2024 Feb 13.

Authors

Taisuke Akamatsu¹, Toshihiro Shirai², Kohei Okawa¹, Keita Hirai³

Affiliations

¹ Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
² Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan. Electronic address: toshihiro-shirai@i.shizuoka-pho.jp.
³ Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Matsumoto, Japan.

PMID: 38360105
DOI: 10.1016/j.anai.2024.02.006

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Asthmatic Agents / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Female
Humans
Interleukin-5 Receptor alpha Subunit / antagonists & inhibitors
Interleukin-5* / antagonists & inhibitors
Interleukin-5* / immunology
Male
Middle Aged
Remission Induction

Substances

Interleukin-5
Anti-Asthmatic Agents
Interleukin-5 Receptor alpha Subunit
Antibodies, Monoclonal, Humanized